Heather Wasserstrom

Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)

Yung‐Jue Bang, Talia Golan, Laëtitia Dahan et al. · European Journal of Cancer · 2020 · 129 citations · Full text

Identification of a Heparin Binding Peptide on the Extracellular Domain of the KDR VEGF Receptor

A. Maureen Dougher, Heather Wasserstrom, Lawrence W. Torley et al. · Growth Factors · 1997 · 94 citations

Extracellular Domain, Vegf165 Binding, Immunology +19

Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).

Yung‐Jue Bang, Talia Golan, Chia‐Chi Lin et al. · Journal of Clinical Oncology · 2019 · 29 citations

Immunology, Immunoediting, Pathology +20

Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).

Yung‐Jue Bang, Talia Golan, Chia‐Chi Lin et al. · Journal of Clinical Oncology · 2018 · 25 citations

Esophageal Cancer, Cancer Management, Immunology +20

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy

Caitlin D. Lowery, Wayne Blosser, Michele Dowless et al. · Oncotarget · 2019 · 17 citations · Full text